Abbott Laboratories (NYSE:ABT | ABT Price Prediction) at $90.53 is a Buy. The healthcare giant has been swept up in a sector-wide rotation out of defensive names, even as its diabetes franchise compounds and its medical devices unit posts double-digit growth.
Abbott spans medical devices, diagnostics, established pharmaceuticals, and nutrition, with Robert B. Ford as CEO. FreeStyle Libre, the continuous glucose monitor, is its fastest-growing engine. Shares have compressed from $127.12 at the Q3 2025 filing to today’s level, dragged lower by sector multiple compression and concerns over the $21 billion Exact Sciences acquisition that closed March 23, 2026.
Why the Selloff Created an Opening
CGM sales hit $2.08 billion in Q1 2026, up 13.8% year over year. The FreeDM2 trial showed Type 2 patients on basal insulin using FreeStyle Libre achieved a 0.6% reduction in HbA1c and 2.5 more hours per day in healthy glucose range versus fingerstick monitoring. This clinical evidence unlocks expansion into basal-insulin users globally.
Medical Devices grew 13.2% to $5.54 billion, with Electrophysiology, Heart Failure, and Rhythm Management all firing. Forward P/E sits at 16, compressed from a trailing P/E of 25. Abbott has posted four straight EPS beats, and management guided full-year adjusted EPS to $5.38 to $5.58.
What the Bears Are Pricing In
Operating income fell 20.32% year over year in Q1, and net income dropped 18.72%. Nutrition shrank 6.0%, and Exact Sciences integration costs will dilute 2026 EPS by $0.20 per share. CGM competition from Dexcom (NASDAQ:DXCM) and Medtronic (NYSE:MDT) is intensifying, and the stock sits well below its 200-day moving average of $113.41, a technical signal that trend followers will avoid until momentum turns.
The Patience Argument
A Hold view says Exact Sciences dilution is real, FX headwinds persist, and the next CGM earnings report on July 20, 2026 will clarify whether the diabetes catalyst is reaccelerating or holding the line. Patient investors could wait for Q2 confirmation before adding.
The Numbers Behind the Verdict
ABT trades at $90.53 against a consensus analyst target of $116.54, implying meaningful upside. Of 27 analysts, 20 rate the stock Buy or Strong Buy, seven say Hold, and none rate it Sell. ABT is down 26.92% year to date while the S&P 500 is up 7.58%, a wide gap of underperformance for a Dividend Aristocrat with 54 consecutive years of dividend hikes and a 2.76% yield.
The Buy Call at $90.53
At $90.53, Abbott is a Buy. International CGM penetration is early, and FreeDM2 data gives Abbott a credible expansion vector into the basal-insulin Type 2 population, a category that dwarfs the Type 1 base CGM was built around. With Medical Devices already growing low double digits, even modest CGM acceleration pushes 2026 EPS toward the upper end of the $5.38 to $5.58 range.
The risk/reward is asymmetric. Downside is cushioned by the dividend, a beta of 0.62, and a forward multiple of 16 that already discounts dilution. Upside reopens if Q2 CGM growth reaccelerates and Exact Sciences contribution scales. The risk/reward looks most attractive up to $95.00. Above that level, the margin of safety narrows.
What would invalidate the call: a CGM growth deceleration below 10%, a botched Exact Sciences integration, or guidance cuts at the July 20 report. Keep an eye on the stock and segment commentary that quarter.
Abbott at $90.53 is a high-quality compounder on sale, and the diabetes franchise is the lever that resets the multiple.
Top Gaining Stocks
Top Losing Stocks